Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy

Inclusion Criteria:

Histological diagnosis of primary RCC
Histological or radiographic diagnosis of metastatic RCC
Age >= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-3
Feasible vascular access as determined by study staff
Undergoing standard of care SBRT or PCA to RCC metastatic lesion(s)
Provide written informed consent
Willing to consent to research blood draws
Willing to return to enrolling institution for follow-up

Exclusion Criteria:

Prior local treatment of the index metastatic lesion
Pregnant or nursing women
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry

Patients receiving prophylactic steroids, defined as initiation of steroids within 1 week prior to local ablative therapy start, including the first day of local ablative therapy.

NOTE: Patients initiating steroids after the first day of local ablative therapy and within 14 days after local ablative therapy completion, will be allowed into the study and the use of steroids will be recorded.